Composition containing eicosapentaenoic acid alkyl ester, and method for producing same

Patent metadata

Field	Value
Publication number	US-10105340-B2
Application number	US-201815878827-A
Country	US
Kind code	B2
Filing date	Jan 24, 2018
Priority date	Sep 17, 2014
Publication date	Oct 23, 2018
Grant date	Oct 23, 2018

Abstract

Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Ton or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

First claim

The invention claimed is:

1. An eicosapentaenoic acid alkyl ester-containing composition which, upon measurement by gas chromatography, comprises 96 to 99 area % of an eicosapentaenoic acid alkyl ester, wherein the content of alkyl esters of saturated fatty acids is 0.5 area % or less, and wherein the composition satisfies at least one of the following (i)-(iv):
(i) the sum of the contents of alkyl esters of n-3 fatty acids having a carbon number of 18 to 22, other than the eicosapentaenoic acid alkyl ester, is 2.0 area % or less,
(ii) the content of an octadecatetraenoic acid (C18:4 n-3) alkyl ester is 0.4 area % or less,
(iii) the content of a nonadecapentaenoic acid (C19:5 n-3) alkyl ester is 0.2 area % or less, and
(iv) the content of an eicosatetraenoic acid (C20:4 n-3) alkyl ester is 0.7 area % or less.

2. The composition of claim 1 , wherein the content of mono-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.

3. The composition of claim 1 , wherein the sum of the contents of mono-trans forms and di-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.

4. The composition of claim 1 , wherein the sum of the contents of mono-trans forms, di-trans forms and tri-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.

5. The composition of claim 1 , wherein the sum of the contents of mono-trans forms, di-trans forms, tri-trans forms and tetra-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.

6. The composition of claim 1 , wherein the content of any one of the mono-trans forms of the eicosapentaenoic acid alkyl ester in which any one of the double bonds at 5-position, 14-position, and 17-position thereof is trans is 0.5 area % or less.

7. The composition of claim 1 , wherein the content of a mono-trans form of the eicosapentaenoic acid alkyl ester in which the double bond at 11-position thereof is trans is 1.0 area % or less.

8. The composition of claim 1 , wherein the content of an arachidonic acid alkyl ester is 0.7 area % or less.

9. The composition of claim 1 , wherein the content of a n-nonadecanoic acid (C19:0) alkyl ester is 0.1 area % or less.

10. The composition of claim 1 , wherein the content of an arachidic acid (C20:0) alkyl ester is 0.2 area % or less.

11. The composition of claim 1 , wherein the content of a-linolenic acid (C18:3 n-3) alkyl ester is 0.2 area % or less.

12. The composition of claim 1 , wherein the content of an icosa-5,9,11,14,17-pentaenoic acid (C20:5 n-3(5,9,11,14,17)) alkyl ester is 0.2 area % or less.

13. The composition of claim 1 , wherein the content of a henicosapentaenoic acid (C21:5 n-3) alkyl ester is 0.2 area % or less.

14. The composition of claim 1 , wherein the content of docosahexaenoic acid (C22:6 n-3) alkyl ester is 0.1 area % or less.

Assignees

• Nippon Suisan Kaisha Ltd
• Mochida Pharm Co Ltd
• Nippon Suisan Kaisha Ltd

Inventors

• Doisaki Nobushige
• Arato Shingo
• Fukae Takuro

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title